KRAS and non-small cell lung carcinoma: Other clinical trials are recruiting to evaluate the feasibility of VS-6766 in combination with sotorasib (NCT05074810) and adagrasib (NCT05375994) in KRAS-G12C-mutant NSCLC subjects.